Organogenesis Q1 Earnings Call Highlights

Organogenesis NASDAQ: ORGO reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following Medicare policy changes and related commentary from the Centers for Medicare & Medicaid Services (CMS).

MarketBeat • May 8, 2026

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 7, 2026

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain

GlobeNewsWire • Apr 28, 2026

What's Going On With Organogenesis Stock On Wednesday?

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares are up during Wednesday's premarket session following positive news regarding a clinical trial for PuraPly AM, which demonstrated statistically significant wound closure for diabetic foot ulcers.

Benzinga • Apr 8, 2026

Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win

The trial demonstrated statistically significant wound closure at 12 weeks when comparing PuraPly AM plus standard of care to standard care alone.

Benzinga • Apr 7, 2026

Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight

Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples due to overestimated short-term reimbursement risks. PuraPly AM achieved statistically significant results in a randomized controlled trial for diabetic foot ulcers, strengthening ORGO's clinical and commercial position. ORGO faces a 25–38% revenue decline in 2026 from CMS reimbursement changes, but RCT-backed evidence de-risks coverage and supports a recovery thesis into 2027.

Seeking Alpha • Apr 7, 2026

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that first quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, May 7th.

GlobeNewsWire • Apr 6, 2026

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administration (FDA) resulting in confirmation to initiate a rolling Biologics Licenses Application (BLA) for ReNu planned before the end of December.

GlobeNewsWire • Apr 6, 2026

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the completion of a randomized controlled trial (RCT) evaluating PuraPly®AM plus standard of care (SOC) versus SOC alone in the management of non-healing diabetic foot ulcers (DFUs).

GlobeNewsWire • Apr 6, 2026